vs
Side-by-side financial comparison of FIRST MID BANCSHARES, INC. (FMBH) and Stoke Therapeutics, Inc. (STOK). Click either name above to swap in a different company.
Stoke Therapeutics, Inc. is the larger business by last-quarter revenue ($158.6M vs $88.2M, roughly 1.8× FIRST MID BANCSHARES, INC.). Stoke Therapeutics, Inc. runs the higher net margin — 71.2% vs 26.8%, a 44.3% gap on every dollar of revenue. On growth, Stoke Therapeutics, Inc. posted the faster year-over-year revenue change (3661.1% vs 3.4%). Stoke Therapeutics, Inc. produced more free cash flow last quarter ($131.7M vs $124.0M).
First Mid Bancshares Inc. is a U.S.-headquartered regional financial services holding company. It provides full-range retail and commercial banking products, wealth management, insurance solutions, and agricultural financing, mainly serving individual consumers, small and medium-sized enterprises, and agricultural clients across multiple Midwestern states including Illinois, Missouri, and Indiana.
Stoke Therapeutics, Inc. is a clinical-stage biotechnology company developing innovative RNA-targeted therapies for severe rare genetic diseases. Its lead candidates address unmet needs for Dravet syndrome, a rare epilepsy, and other neurological monogenic disorders, serving patients across North America and global markets.
FMBH vs STOK — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2025
| Metric | | |
|---|---|---|
| Revenue | $88.2M | $158.6M |
| Net Profit | $23.7M | $112.9M |
| Gross Margin | — | — |
| Operating Margin | 34.0% | 70.2% |
| Net Margin | 26.8% | 71.2% |
| Revenue YoY | 3.4% | 3661.1% |
| Net Profit YoY | 23.5% | 528.0% |
| EPS (diluted) | $0.98 | $1.90 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $88.2M | — | ||
| Q3 25 | $89.3M | — | ||
| Q2 25 | $87.5M | — | ||
| Q1 25 | $84.3M | $158.6M | ||
| Q4 24 | $85.3M | $22.6M | ||
| Q3 24 | $80.6M | — | ||
| Q2 24 | $79.2M | — | ||
| Q1 24 | $79.9M | — |
| Q4 25 | $23.7M | — | ||
| Q3 25 | $22.5M | — | ||
| Q2 25 | $23.4M | — | ||
| Q1 25 | $22.2M | $112.9M | ||
| Q4 24 | $19.2M | $-10.5M | ||
| Q3 24 | $19.5M | — | ||
| Q2 24 | $19.7M | — | ||
| Q1 24 | $20.5M | — |
| Q4 25 | 34.0% | — | ||
| Q3 25 | 32.2% | — | ||
| Q2 25 | 34.4% | — | ||
| Q1 25 | 33.4% | 70.2% | ||
| Q4 24 | 29.7% | -60.4% | ||
| Q3 24 | 31.5% | — | ||
| Q2 24 | 33.7% | — | ||
| Q1 24 | 33.7% | — |
| Q4 25 | 26.8% | — | ||
| Q3 25 | 25.2% | — | ||
| Q2 25 | 26.8% | — | ||
| Q1 25 | 26.3% | 71.2% | ||
| Q4 24 | 22.5% | -46.4% | ||
| Q3 24 | 24.2% | — | ||
| Q2 24 | 24.9% | — | ||
| Q1 24 | 25.6% | — |
| Q4 25 | $0.98 | — | ||
| Q3 25 | $0.94 | — | ||
| Q2 25 | $0.98 | — | ||
| Q1 25 | $0.93 | $1.90 | ||
| Q4 24 | $0.81 | $-0.15 | ||
| Q3 24 | $0.81 | — | ||
| Q2 24 | $0.82 | — | ||
| Q1 24 | $0.86 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $274.8M |
| Total DebtLower is stronger | $354.5M | — |
| Stockholders' EquityBook value | $958.7M | $350.1M |
| Total Assets | $8.0B | $406.9M |
| Debt / EquityLower = less leverage | 0.37× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $274.8M | ||
| Q4 24 | — | $128.0M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $354.5M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $958.7M | — | ||
| Q3 25 | $932.2M | — | ||
| Q2 25 | $894.1M | — | ||
| Q1 25 | $870.9M | $350.1M | ||
| Q4 24 | $846.4M | $229.0M | ||
| Q3 24 | $858.5M | — | ||
| Q2 24 | $813.6M | — | ||
| Q1 24 | $798.0M | — |
| Q4 25 | $8.0B | — | ||
| Q3 25 | $7.8B | — | ||
| Q2 25 | $7.7B | — | ||
| Q1 25 | $7.6B | $406.9M | ||
| Q4 24 | $7.5B | $271.6M | ||
| Q3 24 | $7.6B | — | ||
| Q2 24 | $7.6B | — | ||
| Q1 24 | $7.7B | — |
| Q4 25 | 0.37× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $130.9M | $131.8M |
| Free Cash FlowOCF − Capex | $124.0M | $131.7M |
| FCF MarginFCF / Revenue | 140.6% | 83.0% |
| Capex IntensityCapex / Revenue | 7.8% | 0.1% |
| Cash ConversionOCF / Net Profit | 5.53× | 1.17× |
| TTM Free Cash FlowTrailing 4 quarters | $207.9M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $130.9M | — | ||
| Q3 25 | $33.0M | — | ||
| Q2 25 | $7.7M | — | ||
| Q1 25 | $47.9M | $131.8M | ||
| Q4 24 | $124.4M | $-23.2M | ||
| Q3 24 | $33.1M | — | ||
| Q2 24 | $24.0M | — | ||
| Q1 24 | $29.0M | — |
| Q4 25 | $124.0M | — | ||
| Q3 25 | $31.9M | — | ||
| Q2 25 | $6.0M | — | ||
| Q1 25 | $46.0M | $131.7M | ||
| Q4 24 | $119.5M | $-23.2M | ||
| Q3 24 | $32.0M | — | ||
| Q2 24 | $22.9M | — | ||
| Q1 24 | $27.6M | — |
| Q4 25 | 140.6% | — | ||
| Q3 25 | 35.8% | — | ||
| Q2 25 | 6.8% | — | ||
| Q1 25 | 54.5% | 83.0% | ||
| Q4 24 | 140.0% | -102.7% | ||
| Q3 24 | 39.7% | — | ||
| Q2 24 | 28.9% | — | ||
| Q1 24 | 34.5% | — |
| Q4 25 | 7.8% | — | ||
| Q3 25 | 1.2% | — | ||
| Q2 25 | 2.0% | — | ||
| Q1 25 | 2.3% | 0.1% | ||
| Q4 24 | 5.8% | 0.2% | ||
| Q3 24 | 1.4% | — | ||
| Q2 24 | 1.4% | — | ||
| Q1 24 | 1.9% | — |
| Q4 25 | 5.53× | — | ||
| Q3 25 | 1.47× | — | ||
| Q2 25 | 0.33× | — | ||
| Q1 25 | 2.16× | 1.17× | ||
| Q4 24 | 6.49× | — | ||
| Q3 24 | 1.70× | — | ||
| Q2 24 | 1.21× | — | ||
| Q1 24 | 1.42× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
